Overview

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

Status:
Completed

Trial end date:
2019-12-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in Japanese participants with treatment-resistant depression (TRD), in improving depressive symptoms.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Treatments:

Esketamine